One Project, Five Separate Grant Applications

Grant eligibility is normally a question about one organization. Does your entity type qualify, is your geography in scope, is your budget under the ceiling. You answer it once and the answer holds while you write.

There is a family of currently open federal research listings where that framing produces the wrong answer, because the thing being submitted is not an application. It is a set of applications, filed separately by two to five principal investigators, all due at the same moment. Several records say directly what happens if one does not arrive: the whole set can be pulled.

None of this is in a structured field. Award ceiling is a field, deadline is a field, applicant type is a field. “Failure to submit all associated applications by the deadline may result in administrative withdrawal” is a sentence in a paragraph, and it moves the largest risk in the project onto a person your organization does not employ.

Eight open records, sorted by what actually gets submitted:

The first six are Defense Health Agency Contracting Activity mechanisms. The last two make the pattern legible, because they solve the same coordination problem in two other ways.

The Partnering Mechanism Splits the Filing, Not Just the Work

Start with the Pancreatic Cancer Research Program’s Translational Research Partnership Award, which states the structure in the fewest words.

Per the record, the award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists to accelerate promising pancreatic cancer ideas toward clinical applications, and the partnership must include at least one member with expertise in pancreatic cancer research or patient care. It requires two Principal Investigators, referred to as the Initiating PI and the Partnering PI. Only the Initiating PI submits a pre-application, but both submit at the full application stage, and the Partnering PI’s application is an abbreviated package specific to their distinct portion of the project.

Then the sentence that changes the project management: per the record, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

The scope rules are conventional by comparison: preliminary data supporting feasibility is required, though it need not originate from studies of pancreatic cancer; retrospective tissue analysis, correlative studies and pilot clinical trials are supported but large-scale clinical trials are not; and all applications must address at least one of the FY26 program focus areas.

Read the two halves together and the asymmetry appears. The pre-application stage is single-threaded — one person, one submission. The full application stage is not, and by then the project has been in development for months. The moment of maximum accumulated investment is also the moment a submission you do not control can end it.

The Neurofibromatosis Synergistic Idea Award closes the loophole most people reach for on first hearing this.

Per the record, the award supports synergistic approaches to neurofibromatosis research involving two or three Principal Investigators who use complementary perspectives to address a central problem, and applications must include preliminary and/or published data relevant to NF. One PI is identified as the Initiating PI, responsible for the majority of the administrative tasks associated with submission; an additional one or two are Partnering PIs. Each partner is recognized as a PI, submits a separate application — the record specifies, even if the partners are at the same organization — and receives an individual award.

That parenthetical is the whole point. The plural filing is not a workaround for institutions that cannot share a budget — it is the design. Two investigators down the same hallway still file two applications and still receive two awards.

Five Applications, and a Deadline That Belongs to Everyone

The Transformative Breast Cancer Consortium Award, at up to $35,000,000, is the largest instance of the pattern here, and it scales the risk with the money.

Per the record, applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. All applications must address at least one of the FY26 program overarching challenges, or provide adequate justification for exception.

Structurally: the mechanism allows for up to five Principal Investigators, which includes the Consortium Director and three or four Project Team PIs. Only the Consortium Director submits a pre-application, but all PIs submit at the full application stage. Per the record, failure to submit all associated applications by the full application deadline may result in administrative withdrawal.

Five filings, one deadline, one consequence. Note where the coordination burden sits: the Consortium Director carries a project whose completion depends on four other institutions’ submission queues, each with its own sponsored-programs office and internal review window.

The Melanoma Research Program’s Team Science Award adds a second gate on top of the first. Per the record, the mechanism requires at least two and up to three PIs who partner to jointly design and execute a single research project, and if recommended for funding each PI is named on separate awards to the recipient organizations. Only the Initiating PI submits the pre-application; all PIs submit full applications.

The gate: per the record, after submitting the required pre-application, investigators must receive an invitation to submit a full application. Collaborative relationships with the melanoma consumer community are encouraged under a Consumer Collaboration Option, but not required.

So the sequence is one submission, a wait for an invitation, then two or three submissions on a shared deadline. A team assembled after the invitation has less time to file than the deadline suggests.

Some Team Members Are Not Scientists, and You Have to Find Them

Three of these records require a person no institutional directory will return.

The Transformative Breast Cancer Consortium Award, per the record, requires at least one breast cancer consumer advocate per project team — not per consortium. On a consortium with four project teams, that is four advocates.

The Breast Cancer Breakthrough Award Level 3 goes further on a smaller mechanism. Per the record, the research team must include two or more breast cancer consumer advocates. This mechanism is more flexible on the filing question — it allows a single Principal Investigator, or two partnering PIs under the Partnering PI Option, in which case only the Initiating PI submits a pre-application but both submit at the full application stage, and failure to submit all associated applications by the deadline may result in administrative withdrawal. The Breakthrough mechanism runs four funding levels, each with a distinct research scope; this listing is Level 3.

The Melanoma Focused Program Award – Rare Melanomas carries the requirement as a change flagged on the record itself. Per the record, and marked Updated for FY26, investigators must include at least one rare melanoma survivor or patient advocate as part of the project team, who will provide advice and consultation throughout planning, implementation and results dissemination. The rest of the structure matches its sibling: at least two but not more than three distinct but complementary research projects, an Initiating PI plus one or two Partnering PIs, each expected to be a Project Leader for one project, separate awards if funded, and an invitation required after the pre-application.

Put the advocate requirement next to the plural-filing requirement and the recruiting problem is clearer than either alone. One asks you to find a co-investigator whose institution can file on your timeline. The other asks you to find someone with a specific lived experience willing to work on a research team for years. Neither search starts after you read the deadline field.

One Application, Several Awards — the Inverse Case

The NIH Collaborative International Research Project parent announcement solves a similar coordination problem in the opposite direction, and it is worth reading precisely because it looks like the others and is not.

Per the record, this opportunity implements an award structure of prime domestic awards with independent foreign awards that are linked to the prime, giving NIH oversight capacity for international collaborations and letting it track international funding, as identified in NOT-OD-25-104. All applications must include at least one international subproject. The application is evaluated as a whole, and the international subprojects are evaluated on whether the project presents special opportunities through the use of unusual talent, resources, populations, or environmental conditions in other countries that are not readily available in the United States.

The record is equally specific about what the announcement is not for: foreign consultants, purchasing unique equipment or supplies from foreign vendors, or foreign collaborations that would not result in a foreign subaward.

So the plurality here is in the awards, not the applications. One package is evaluated as a whole; several linked awards come out the other side, and the submission risk stays with the domestic prime. The record states no award ceiling — see the listing for current terms.

The NSF MultiPLEx program is a third arrangement again. Per the record, proposals must partner with at least two countries other than the U.S., awards run $200,000 to $2,500,000, a typical award is up to three years, and there is no fixed deadline — proposals may be submitted any time unless a Dear Colleague Letter specifies otherwise.

The structural fact worth extracting: per the record, MultiPLEx funds support the U.S. research team, and research partners should seek funding from their own national funding agencies or from other sources. The partnership is mandatory; the partner’s money is not this program’s problem. The record also warns that proposals must fall outside the scope of existing OISE or directorate programs, and that a proposal not responsive to the program description may be transferred to another OISE program or returned without review.

Three required partnerships, three different answers to who files and who gets paid. The word “partnership” in a title tells you none of it.

Questions to Ask Before You Commit to a Partner Mechanism

The habit is small: before the science conversation, resolve the mechanics.

How many separate applications must arrive, and by when? One, two, three, or five — this set contains all four answers, always in the distinctive-features prose rather than anywhere structured.

What happens if one does not arrive? Four of these records answer explicitly: administrative withdrawal of the associated applications. Treat a partner’s internal submission deadline as your deadline.

Is there an invitation gate before the plural stage? Both melanoma mechanisms require an invitation after the pre-application, which compresses the window in which several institutions must move together.

Does a required team member have to be recruited from outside research? Two or more consumer advocates, one per project team, or one survivor or patient advocate — depending on the record. Start that search early, and treat it as a real commitment to the person, not a checkbox.

Who pays the partner? Each PI receives an individual award on the DoD mechanisms; foreign awards are linked to a domestic prime on the NIH structure; the international partner funds itself on MultiPLEx.

Common Questions

Is a “partnering” mechanism the same as a subaward? Not in this set. On the DoD mechanisms above, the record describes separate applications and individual awards to each PI’s organization — a different arrangement from one prime holding a subaward. The NIH parent announcement is the one that explicitly runs on subawards, and it says so.

Can two investigators at the same institution use a partnering mechanism? The Neurofibromatosis Synergistic Idea Award record addresses this directly: partners submit separate applications even if they are at the same organization. Other records here encourage multi-institutional partnerships without stating they are required — read each on its own terms.

Do these rules apply to federal grants generally? No. Everything above comes from eight specific open listings, most of them Department of Defense medical research mechanisms administered through the Defense Health Agency Contracting Activity. Most federal listings are single-applicant. The point is that the exception exists, is currently open, and is invisible unless you read the full description.

Where does this sit in a listing? In a “Distinctive Features” block or equivalent prose near the end of the summary — after the scientific scope, which is where most readers stop.

Every deadline, dollar figure, team-composition rule and submission requirement above comes off the indexed record for the program it describes, fetched for this post. Where a record states no award range — the NIH parent announcement — this post says so and links the listing rather than supplying a number. Nothing here predicts an outcome for any applicant, and program terms change between fiscal years; confirm every term against the official listing before it becomes a plan.

For related reading, our tips and resources archive collects this kind of listing-reading habit, the federal grants hub covers the agencies these mechanisms come from, the knowledge base goes into award structures and subawards, and the funder directory is the faster route when the question is about one agency across several of its programs.

Finding a partnering mechanism before its pre-application deadline requires searching the full program description, not the deadline field. OpenGrants indexes more than 43,000 open funding opportunities across federal, state, local, foundation and corporate sources, refreshed daily (both verified 2026-08-10). Every new account starts with a free 7-day trial at ops.opengrants.io, and it is $9/month after that (both verified 2026-08-31).